Japan's Chugai applies for approval of antibody treatment for COVID-19
29/06/2021 09:19
TOKYO, June 29 (Reuters) - Chugai Pharmaceutical Co 4519.T
said on Tuesday it applied for regulatory approval in Japan of
an antibody treatment for COVID-19.
The filing is for the antibody cocktail casirivimab and
imdevimab and is based on results from a global phase III study
and a phase I trial in Japan. Chugai in December in-licensed the
drug from Roche ROG.S , which has a controlling stake in the
Japanese company.
(Reporting by Rocky Swift, editing by Louise Heavens)
((rocky.swift@thomsonreuters.com;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)